Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) had its target price boosted by Oppenheimer Holdings, Inc. from $4.00 to $7.00 in a report issued on Thursday morning, Marketbeat Ratings reports. They currently have an outperform rating on the biotechnology company’s stock.
A number of other analysts have also issued reports on CATB. Citigroup Inc. restated a hold rating and set a $1.50 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, September 29th. HC Wainwright raised their target price on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a buy rating in a research report on Monday, August 14th. Finally, Wedbush restated an outperform rating and set a $4.00 target price on shares of Catabasis Pharmaceuticals in a research report on Wednesday, June 21st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Catabasis Pharmaceuticals currently has a consensus rating of Buy and an average target price of $5.42.
Catabasis Pharmaceuticals (CATB) traded down 12.32% during mid-day trading on Thursday, hitting $2.49. 2,521,880 shares of the stock traded hands. The stock’s 50 day moving average is $2.00 and its 200-day moving average is $2.00. The company’s market cap is $55.98 million. Catabasis Pharmaceuticals has a 12 month low of $1.08 and a 12 month high of $5.51.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.08. On average, equities research analysts anticipate that Catabasis Pharmaceuticals will post ($1.39) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://transcriptdaily.com/2017/10/08/catabasis-pharmaceuticals-inc-catb-price-target-raised-to-7-00.html.
Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC acquired a new position in shares of Catabasis Pharmaceuticals in the 1st quarter valued at $106,000. Oppenheimer & Co. Inc. acquired a new position in shares of Catabasis Pharmaceuticals in the 1st quarter valued at $144,000. Finally, Virtu KCG Holdings LLC acquired a new position in shares of Catabasis Pharmaceuticals in the 2nd quarter valued at $271,000. Institutional investors own 32.90% of the company’s stock.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.